Jointly provided by
Support for this activity has been provided through educational grants from Bristol-Myers Squibb; Celgene; Onyx Pharmaceuticals, an Amgen subsidiary; and Takeda Oncology.
Release date: 5/26/2016
Expiration date: 5/26/2017
Estimated time to complete: 1.25 hours
This Virtual Practice features two interactive modules that focus on key elements of multiple myeloma (MM) management. The modules bring to life strategies for optimizing treatment outcomes and review new and emerging therapies and how they can be applied in practice.
- The main conference room features RME Presents…, a presentation that reviews the newest data on myeloma diagnosis and management and follows a patient case through the course of his disease.
- In the staff conference room, a panel of myeloma experts has convened to answer challenging clinical questions on the management of MM patients in the latest edition of RME Hot Seat. These questions—posed by practicing hematologist-oncologists—address the use of elotuzumab vs daratumumab in patients with relapsed/refractory disease, determining which agent to use at disease progression in lenalidomide-sensitive patients, the potential use of PD-1 inhibitors in combination therapy, and several other subjects of relevance to clinicians who see MM patients.
A. Keith Stewart, MBChB—Program Chair
Sergio Giralt, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Thomas G. Martin, III, MD
University of California, San Francisco Medical Center
San Francisco, California
María-Victoria Mateos, MD, PhD
University Hospital of Salamanca
Suzanne Trudel, MD
Princess Margaret Cancer Centre
University Health Network
Toronto, Ontario, Canada
Saad Z. Usmani, MD
The University of North Carolina at Chapel Hill
Levine Cancer Institute
Carolinas Healthcare System
Charlotte, North Carolina
This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with MM.
Upon completion of this activity, participants should be able to:
- Apply and interpret cytogenetic, molecular, and other standard diagnostic and staging tests to define MM patient subsets
- Distinguish between the indicated uses, mechanisms of action, depth and duration of clinical responses, and safety of current agents
- Outline a treatment plan for newly diagnosed patients to achieve the deepest and most durable response while balancing the risk for toxicities
- Outline a treatment plan for patients who have relapsed from or are refractory to their treatment
Accreditation and Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Penn State College of Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Penn State College of Medicine is committed to offering CME programs that promote improvements or quality in health care and are developed free of the control of commercial interests. Reasonable efforts have been taken to ensure that our programs are balanced, independent, objective, scientific, and in compliance with regulatory requirements. Faculty, course directors, and planners have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest. Disclosure of a relationship is not intended to suggest or condone bias but is made to provide participants with information that might be of potential importance to their evaluation of this educational activity. Disclosures are as follows:
A. Keith Stewart, MBChB, has disclosed the following relevant financial relationships:
Consultant/Advisor: Bristol-Myers Squibb, Celgene, Janssen, Novartis
Sergio Giralt, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Jazz Pharmaceuticals, Onyx Pharmaceuticals, Sanofi, Takeda Oncology
Research Grant: Celgene, Sanofi, Takeda Oncology
Thomas G. Martin, III, MD, has disclosed the following relevant financial relationships:
Speakers Bureau: Millennium
María-Victoria Mateos, MD, PhD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Celgene, Janssen, Onyx Pharmaceuticals, Amgen, Takeda Oncology
Speakers Bureau: Amgen, Celgene, Janssen
Suzanne Trudel, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Celgene, Novartis
Research Grant: GlaxoSmithKline, OncoEthix
Speakers Bureau: Celgene
Stock Ownership: Biogene, Celgene, Epizyme, Karyopharm, Roche
Saad Z. Usmani, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Array BioPharma, Bristol-Myers Squibb, Celgene, Janssen, Onyx Pharmaceuticals, Sanofi, Takeda Oncology
Research Grant: Array BioPharma, Janssen, Onyx Pharmaceuticals, Sanofi
Speakers Bureau: Celgene, Onyx Pharmaceuticals, Takeda Oncology
Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Multiple Myeloma Research Foundation
Staff involved in the development and review of this activity have disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships.
Barbara Zosh, Director of Operations, has disclosed no relevant financial relationships.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, Penn State College of Medicine, and the Multiple Myeloma Research Foundation do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, Penn State College of Medicine, the Multiple Myeloma Research Foundation, Bristol-Myers Squibb, Celgene, Takeda Oncology, or Onyx Pharmaceuticals, an Amgen subsidiary. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact Penn State Continuing Education at (717) 531-6483 or ContinuingEd@hmc.psu.edu. Please reference activity code G5980-16-T.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or firstname.lastname@example.org.
- Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
- A computer with an Internet connection
- Internet browser (PC): Google Chrome, Internet Explorer 9 or higher, or Firefox 26 or higher
- Internet browser (Mac): Google Chrome, Firefox 26 or higher, or Safari 5 or higher
- Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required
Copyright © 2016 Penn State College of Medicine, the Multiple Myeloma Research Foundation, and RedMedEd. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.